The efficacy of CEA and CA15-3 tumor markers in monitoring breast cancer was evaluated in 1365 patients with either benign (n = 534) or malignant (n = 831) breast diseases. Thirty-nine breast cancer patients were monitored before and after neoadjuvant chemotherapy. Three hundred forty-nine patients were monitored during post-surgical follow-up for either a minimum of 5 years or until time of recurrence. Twenty-one patients with metastases were also monitored during chemotherapy. Elevated CA 15-3 and TPS levels were found in 28.6% and 30.0% of patients. CA 15-3 and TPS sensitivities rose to 71.9% and 66.3% in metastatic patients, respectively. The addition of TPS to CA 15-3 increased the sensitivity up to 44.4% in the overall population, and to 87.6% in patients with metastases. During post-surgical follow-up CA 15-3 was elevated in 65.7% and TPS in 61.3% of patients with recurrence. The combination of TPS and CA 15-3 increased the overall sensitivity by 12.7%. Longitudinal monitoring of metastatic patients undergoing chemotherapy demonstrated that, when positive, both CA 15-3 and TPS paralleled response to treatment. TPS monitoring may provide additional value when used in combination with CA15-3 during post-surgical follow-up of breast cancer patients.

D'Alessandro, R., Roselli, M., Ferroni, P., Mariotti, S., Spila, A., Aloe, S., et al. (2001). Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer. BREAST CANCER RESEARCH AND TREATMENT, 68(1), 9-19.

Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer

ROSELLI, MARIO;BUONOMO, ORESTE CLAUDIO;
2001-07-01

Abstract

The efficacy of CEA and CA15-3 tumor markers in monitoring breast cancer was evaluated in 1365 patients with either benign (n = 534) or malignant (n = 831) breast diseases. Thirty-nine breast cancer patients were monitored before and after neoadjuvant chemotherapy. Three hundred forty-nine patients were monitored during post-surgical follow-up for either a minimum of 5 years or until time of recurrence. Twenty-one patients with metastases were also monitored during chemotherapy. Elevated CA 15-3 and TPS levels were found in 28.6% and 30.0% of patients. CA 15-3 and TPS sensitivities rose to 71.9% and 66.3% in metastatic patients, respectively. The addition of TPS to CA 15-3 increased the sensitivity up to 44.4% in the overall population, and to 87.6% in patients with metastases. During post-surgical follow-up CA 15-3 was elevated in 65.7% and TPS in 61.3% of patients with recurrence. The combination of TPS and CA 15-3 increased the overall sensitivity by 12.7%. Longitudinal monitoring of metastatic patients undergoing chemotherapy demonstrated that, when positive, both CA 15-3 and TPS paralleled response to treatment. TPS monitoring may provide additional value when used in combination with CA15-3 during post-surgical follow-up of breast cancer patients.
lug-2001
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/06 - ONCOLOGIA MEDICA
Settore MED/05 - PATOLOGIA CLINICA
Settore MED/18 - CHIRURGIA GENERALE
English
Con Impact Factor ISI
Sensitivity and Specificity; Disease-Free Survival; Humans; Aged; Italy; Carcinoma, Lobular; Aged, 80 and over; Adult; Neoplasm Metastasis; Adolescent; Tumor Markers, Biological; Fibrocystic Breast Disease; Neoplasm Staging; Neoadjuvant Therapy; Breast Neoplasms; Postoperative Period; Longitudinal Studies; Mucin-1; Case-Control Studies; Carcinoma, Ductal, Breast; Mastectomy; Middle Aged; Peptides; Neoplasm Recurrence, Local; Female
D'Alessandro, R., Roselli, M., Ferroni, P., Mariotti, S., Spila, A., Aloe, S., et al. (2001). Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer. BREAST CANCER RESEARCH AND TREATMENT, 68(1), 9-19.
D'Alessandro, R; Roselli, M; Ferroni, P; Mariotti, S; Spila, A; Aloe, S; Carone, M; Abbolito, M; Carlini, S; Perri, P; Ricciotti, A; Botti, C; Conti, F; Vici, P; Chiappetta, N; Cognetti, F; Buonomo, Oc; Guadagni, F
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/100940
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 35
  • ???jsp.display-item.citation.isi??? 31
social impact